Wilson's disease in patients with mental disorders;Morbus Wilson als differenzialdiagnose bei psychischen störungen

Nervenheilkunde

Volumn 26, Issue 3, 2007, Pages 150-155

  Bux, Christoph J ^a   Rosenbohm, A ^a   Connemann, B J ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Ceruloplasmin; Copper metabolism; Mental disorders; Wilson's disease

Indexed keywords

COPPER; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC;

AUTOSOMAL RECESSIVE DISORDER; COPPER BLOOD LEVEL; COPPER METABOLISM; DIFFERENTIAL DIAGNOSIS; GENETIC ANALYSIS; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; MENTAL DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT; WILSON DISEASE;

EID: 34347344905     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626842     Document Type: Review

References (22)

1. Akil M, Brewer GJ. Psychiatric and Behavioral Abnormalities in Wilson's Disease. Behav Neurol Movement Disorders 1995; 65: 171-78.
2. Akil M et al. The psychiatric presentations of Wilson's disease. J Neuropsychiatry 1991; 3: 377-82.
3. Barceloux DG. Copper. Clinical Toxicology 1999; 37: 217-30.
4. Brewer GJ et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 2006; 63: 521-7.
5. Brewer GJ, Askari F. Wilson's disease: clinical management and therapy. J Hepatol 2005; 42: S13-21.
6. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 1987; 44: 490-3.
7. Brewer GJ. Behavioral abnormalities in Wilson's disease. Adv Neurol 2005; 96: 262-74.
8. Brewer GJ. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment. CNS Drugs 2005; 19: 185-92.
9. Cauza E et al. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997; 27: 358-62.
10. Cox DW, Roberts EA. Wilson Disease. (online) GeneClinics, University of Washington, Seattle 2006. URL: http://www.geneclinics.org/profiles/wilson/ details.html.
11. Dening TR, Berrios GE. Wilson's disease: psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989; 46: 1125-34.
12. Ferenci P. Pathophysiology and clinical features of Wilson's disease. Metab Brain Dis 2004; 19: 229-39.
13. Ferenci P. Wilson's Disease. Clin Gastroenterol Hepatol 2005; 3: 726-33.
14. Fleischer B. Zwei weitere Fälle von grünlicher Verfärbung der Kornea. Klin Mbl Augenheilk 1903; 41: 489-91.
15. Frydman M et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA 1985; 82: 1819-21.
16. Harada M. Wilson disease. Med Electron Microsc 2002; 35: 1-6.
17. Harris ZL. Not all absent serum Ceruloplasmin is Wilson Disease: A review of Aceruloplasminemia. J Investig Med 2002; 50: 236-8.
18. Hermann W et al.. M. Wilson. In: Diener HC (Hrsg). Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme 2005.
19. Hitoshi S, Iwata M, Yoshikawa K. Mid-brain pathology of Wilson's disease: MRI analysis of three cases. J Neurol Neurosurg Psychiatry 1991; 54: 624-6.
20. Holtzman NA, Gaumnitz BM. Studies on the rate of release and turnover of coeruloplasmin and apocoeruloplasmin in rat plasma. J Biol Chem 1970; 245: 2354-8.
21. Jacobs DA, Markowitz CE, Liebeskind DS, Galetta, SL. The "double panda sign" in Wilson's disease. Neurology 2003; 61: 969.
22. Jukic I et al. Psychosis and Wilson's disease: a case report. Psychiatr Danub 2006; 18: 105-7.